About
iRhythm Technologies, Inc. is a digital healthcare company, which engages in the provision of design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services. It also provides solutions that detect, predict, and prevent disease. The company was founded by Uday N. Kumar in September 2006 and is headquartered in San Francisco, CA.
Current Value
$101.651 Year Return
Current Value
$101.651 Year Return
Key Details
Market Cap
$3.33B
P/E Ratio
-29.12
1Y Stock Return
-1.30%
1Y Revenue Growth
20.13%
Dividend Yield
0.00%
Price to Book
36.6
Strategies that include IRTC
Double maintains 2 strategies that include IRTC - iRhythm Technologies, Inc.
Health Care Sector
Medium risk
$14.0K
This Strategy focuses on healthcare companies, including pharmaceuticals, biotechnology, healthcare providers, and medical equipment firms. Offering exposure to a sector driven by demographic trends and ongoing medical advancements, it's a strategic choice for investors considering healthcare's long-term growth potential.
Top Sector
Health Care
Top Holdings
Bktd. Return
Expense Ratio
0.00%
Holdings
346
Stock's related to IRTC
The stocks that are correlated to IRTC - iRhythm Technologies, Inc. are MLI, ENOV, ENVA, GTLS, CLNE
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| 35.98% | $8.39B | +40.33% | 1.19% | |
E ENOVEnovis Corp. | 34.31% | $1.92B | -43.41% | 0.00% |
| 34.06% | $2.38B | +48.62% | 0.00% | |
| 33.79% | $5.70B | -18.63% | 0.00% | |
| 33.50% | $333.17M | -41.11% | 0.00% | |
S SDGRSchrödinger, Inc. | 33.31% | $1.38B | -27.56% | 0.00% |
| 33.01% | $10.69B | +1.31% | 0.00% | |
C CADECadence Bank | 32.90% | $5.04B | +0.33% | 3.90% |
R RIOTRiot Platforms, Inc. | 32.86% | $2.56B | -28.36% | 0.00% |
| 32.43% | $3.70B | -20.25% | 2.20% | |
Y YELPYelp, Inc. | 31.73% | $2.41B | -7.69% | 0.00% |
I IMNMImmunome, Inc. | 31.68% | $542.57M | -69.20% | 0.00% |
| 31.65% | $73.01M | -82.71% | 0.00% | |
H HUTHut 8 Corp. | 31.64% | $1.24B | +22.91% | 0.00% |
C CYRXCryoPort, Inc. | 31.48% | $271.51M | -70.69% | 0.00% |
G GATXGATX Corp. | 31.38% | $5.30B | +12.67% | 1.65% |
A ATRCAtriCure, Inc. | 31.02% | $1.61B | +25.89% | 0.00% |
| 30.84% | $1.10B | +171.43% | 0.00% | |
C CHGGChegg, Inc. | 30.82% | $59.51M | -91.98% | 0.00% |
| 30.66% | $534.33M | +10.17% | 8.38% | |
ETF's related to IRTC
The ETFs that are correlated to IRTC - iRhythm Technologies, Inc. are CPRJ, XHE, QQA, HEAL, CPSJ
Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| 43.28% | $48.65M | 0.69% | |
| 41.97% | $176.51M | 0.35% | |
| 41.85% | $188.92M | 0% | |
| 38.87% | $34.93M | 0.68% | |
| 37.08% | $33.02M | 0.69% | |
| 35.22% | $1.98B | 0.2% | |
| 34.93% | $157.51M | 0.65% | |
A ARKKARK Innovation ETF | 34.72% | $5.16B | 0.75% |
| 34.24% | $466.36M | 0.35% | |
| 34.08% | $79.32M | 0.85% | |
| 34.04% | $903.52M | 0.75% | |
| 34.01% | $269.57M | 0.68% | |
| 33.70% | $6.33B | 0.51% | |
| 33.66% | $4.63B | 0.4% | |
| 33.59% | $798.51M | 0.6% | |
| 33.35% | $10.93B | 0.24% | |
| 33.33% | $809.63M | 0.6% | |
| 33.23% | $20.26B | 0.05% | |
| 33.22% | $320.39M | 0.79% | |
| 33.11% | $63.84B | 0.19% | |
News
Yahoo
With the business potentially at an important milestone, we thought we'd take a closer look at iRhythm Technologies...
Yahoo
Looking back on patient monitoring stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including iRhythm (NASDAQ:IRTC) and its peers.
Yahoo
Two large studies of over one million patients reveal that short-term Holter-duration monitoring frequently misses actionable arrhythmias and that patient-reported symptoms are an unreliable predictor of arrhythmic eventsSAN FRANCISCO, March 31, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) today announced results from two large real-world retrospective analyses presented at the American College of Cardiology (ACC) 2025 Scientific Sessions in Chicago, IL. Drawing on data from
Finnhub
Two large studies of over one million patients reveal that short-term Holter-duration monitoring frequently misses actionable arrhythmias and that patient-reported symptoms are an unreliable predictor...
Yahoo
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 5.9%. This performance was discouraging since the S&P 500 held steady.
Yahoo
Let’s dig into the relative performance of Insulet (NASDAQ:PODD) and its peers as we unravel the now-completed Q4 patient monitoring earnings season.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
0% Expense Ratios with TLH
We offer over 50 indexes with zero expense ratios.
Registration will take about 10 seconds